By targeting multiple pathways, these medications offer hope for better management and improved quality of life
Silencing SHMT2 suppressed these malignant phenotypes, while reintroducing MTHFD1L restored them, suggesting that targeting the hypoxia-driven SHMT2 lactylation pathway may offer a promising therapeutic strategy in EC [180]
NAD levels decline as we age, yet our cells often need more to help us during the aging process
Rosenstock J, Frias J, Jastreboff AM, et al
Manufactured in a GMP-certified and FDA-registered facility
2 Pharmacotherapy in obesity and BED: a difficult legacy Pharmacological treatment of obesity has historically faced significant limitations, with many agents demonstrating only moderate efficacy and a high incidence of adverse effects [24, 25]